Attorney Docket No.: 1340-1-017

1. (Amended) An isolated polypeptide <u>useful in a vaccine</u> [comprising] <u>having</u> an amino acid sequence of a N-terminal choline binding protein A truncate, <u>wherein said amino</u> acid sequence is selected from the sequence set forth in SEQ ID NO 1, active fragments thereof, conserved variants thereof, mutants thereof, analogs thereof, and derivatives thereof.

;

- 2. (Amended) The isolated polypeptide of Claim 1, wherein <u>said polypeptide is</u> <u>immunogenic against bacterial infection</u> [the amino acid sequence is set forth in SEQ ID NO 1, including fragments, mutants, variants, analogs, or derivatives, thereof].
- 3. (Amended) The isolated polypeptide of claim 1, wherein the amino acid sequence is selected from the group consisting of the sequence set forth in SEQ ID NO 3, [including] active fragments thereof, mutants thereof, conserved variants thereof, analogs thereof, [or] and derivatives[,] thereof.
- 5. (Amended) The isolated polypeptide of claim 1, wherein the amino acid sequence is selected from the group consisting of the sequence set forth in SEQ ID NO 7, [including] active fragments thereof, mutants thereof, variants thereof, analogs thereof, [or] and derivatives[,] thereof.
- 6. (Amended) The isolated polypeptide of claim 1, wherein the amino acid sequence is selected from the group consisting of the sequence set forth in SEQ ID NO 9, [including] active fragments thereof, mutants thereof, conserved variants thereof, analogs thereof, [or] and derivatives[,] thereof.
- 7. (Amended) An isolated polypeptide [comprising] <u>having</u> an amino acid [sequence] of a N-terminal choline binding protein A truncate having the amino acid <u>sequence</u> as set forth in SEQ ID NO 24, wherein the polypeptide exhibits [its] <u>a</u> tertiary structure.
- 9. (Amended) The isolated polypeptide of claim 7, wherein the polypeptide is made by cleaving a full length choline binding protein A with hydroxylamine, wherein the hydroxylamine cleaves the choline binding protein A at a location corresponding to [amino]

acid] <u>position</u> 475 in the consensus sequence set forth in Figure 2, thereby creating the N-terminal choline binding protein A truncate.

;

- 13. (Amended) An isolated polypeptide comprising an amino acid sequence of a N-terminal choline binding protein A truncate, wherein the polypeptide has lectin activity and does not bind to choline, and wherein said amino acid sequence is selected from the group consisting of SEQ ID NOS 1, 3-7 and 9-11, active fragments, conserved variants, analogs and derivatives thereof.
- 14. (Amended) An isolated immunogenic polypeptide [comprising] <u>having</u> an amino acid sequence of a N-terminal choline binding protein A truncate, and wherein said amino acid sequence is selected from the group consisting of SEQ ID NOS 1, 3-7 and 9-11, active fragments, conserved variants, analogs and derivatives thereof.
- 15. (Amended) The immunogenic polypeptide of claim 14, wherein the amino acid sequence is set forth in SEQ ID NO 1[, including fragments, mutants, variants, analogs, or derivatives, thereof].
- 16. (Amended) The immunogenic polypeptide of claim 14, wherein the amino acid sequence is set forth in SEQ ID NO 3[, including fragments, mutants, variants, analogs, or derivatives, thereof].
- 17. (Amended) The immunogenic polypeptide of claim 14, wherein the amino acid sequence is set forth in SEQ ID NO 7[, including fragments, mutants, variants, analogs, or derivatives, thereof].
- 18. (Amended) The immunogenic polypeptide of claim 14, wherein the amino acid sequence is set forth in SEQ ID NO 9[, including fragments, mutants, variants, analogs, or derivatives, thereof].
- 39. (Amended) A pharmaceutical composition <u>for use as a vaccine</u> comprising an <u>immunogenic</u> amount of the polypeptide of claim 1 and a pharmaceutically acceptable <u>adjuvant</u>, carrier or diluent.